Etoposide
- PDF / 169,751 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 35 Downloads / 178 Views
1 S
Leucopenia and enterococcal infection following off-label use: case report In a study of 11 patients diagnosed with COVID-19, a 60-year-old woman was described, who developed enterococcus infection and leucopenia following off-label treatment with etoposide for COVID-19. The woman (patient #5 from the article), was admitted following diagnosis of COVID-19 with acute respiratory distress syndrome (ARDS). She was thus put on oxygen support. Her medical history was significant for obesity and hypertension. Initially, she received off-label treatment with lopinavir/ritonavir, methylprednisolone, unspecified antimicrobials and an unspecified interleukin inhibitor. She also received enoxaparin for prophylaxis of thromboembolism. Thereafter, off-label adjuvant salvage treatment with etoposide 100 mg/m2 [route not stated] was initiated for the COVID-19. She was later transferred to the ICU and required mechanical ventilation. She received a total of two doses of etoposide. The severe ARDS resolved subsequently; however, she developed leucopenia and enterococcus infection, which were considered as etoposide toxicity [durations of treatments to reactions onsets not stated]. She was then shifted out of the ICU. On day 24, she died presumably due to a massive pulmonary thromboembolism [aetiology not stated]. Autopsy was not performed [outcomes of the reactions not stated]. M M-B, et al. Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients. Journal of Infection 81: 468-470, No. 3, Sep 2020. Available from: 803499085 URL: http://doi.org/10.1016/j.jinf.2020.06.006
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
Data Loading...
